Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SynairgenSYGGF EV-to-EBITDA is 0.57 as of Jul. 29, 2026.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Synairgen's enterprise value is $-5.97 Mil.
Synairgen's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-10.51 Mil. Therefore, Synairgen's EV-to-EBITDA for today is 0.57.
The historical rank and industry rank for Synairgen's EV-to-EBITDA or its related term are showing as below:
SYGGF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 11.7 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Synairgen (OTCPK:SYGGF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Synairgen's share price for today is $0.0001.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Synairgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.029.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Synairgen's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SYGGF vs RGBP, CNBX, SIGY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Synairgen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synairgen EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synairgen's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Synairgen's EV-to-EBITDA falls into.
Synairgen's current Enterprise Value is $-5.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Synairgen's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-10.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synairgen (SYGGF) has a EV-to-EBITDA of 0.57 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Synairgen.
Is Synairgen's EV-to-EBITDA too high?
Synairgen's current EV-to-EBITDA is 0.57. The Biotechnology industry median EV-to-EBITDA is 11.70. Synairgen's value of 0.57 is 95.1% below this industry median.
How does Synairgen's EV-to-EBITDA compare to RGBP and CNBX?
Synairgen's EV-to-EBITDA of 0.57 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 11.70. Synairgen's value of 0.57 is 95.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.70, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synairgen's current EV-to-EBITDA of 0.57 is 95.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Synairgen. For the Biotechnology industry, the median EV-to-EBITDA is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synairgen's current EV-to-EBITDA is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synairgen stock overvalued right now?
Synairgen (SYGGF) has a current EV-to-EBITDA of 0.57. The current EV-to-EBITDA is 0.57 and 95.1% below the Biotechnology industry median of 11.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Synairgen (SYGGF), the current EV-to-EBITDA is 0.57 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYGGF has been successfully added to your 
